This trial is evaluating whether Decitabine and Cedazuridine will improve 1 primary outcome and 5 secondary outcomes in patients with Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Measurement will happen over the course of At 12 months.
This trial requires 70 total participants across 1 different treatment group
This trial involves a single treatment. Decitabine And Cedazuridine is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"Over the past 10 years, the development of CDDP for the treatment of AML and MDS has been largely uneventful except for the introduction of CDDP as monotherapy. However, recent studies have demonstrated that CDDP is active against CMML and provided a rationale for the exploration of CDDP in this indication. Results from recent clinical trials have confirmed the effectiveness of CDDP in patients with CMML. This agent appears to be well tolerated with no significant side effects. Further data are awaited before clinical recommendations regarding the use of CDDP in CMML can be made." - Anonymous Online Contributor
"No new treatments and treatments are available for AML, CML, and CMLCP, which are currently treated with standard chemotherapy regimens. However, it should be noted that there have been many advances in research on the development of novel therapies. New drug developments include [bortezomib] (Velcade), [everolimus] (Afinitor), [Rituxan] (Rituxan), [atasiban] (Copanlisib), [ibritumomab tiuxetan] (Zevalin), [pomalidomide] (Entycal), and alemtuzumab (Campath)." - Anonymous Online Contributor
"Findings from a recent study suggest that while Dec plus Ceda does not appear to be an effective therapy in the treatment of smoldering AML, it may be useful in preventing relapses and prolonging survival, particularly in patients with B-CLL." - Anonymous Online Contributor
"There are still many questions to be answered about the pathogenesis of CML and how we might better treat it. Some aspects of this disease are becoming clearer, such as its potential to develop into acute myelogenous leukemia with minimal change disease. Some other new findings from recent studies include new insights into epigenetic mechanisms, gene expression and splicing, and the role of microRNAs in progression of CML. Improvements in our understanding of the biology of CML will hopefully lead to improved treatments. For example, identification of the mechanisms underpinning resistance to tyrosine kinase inhibitors (TKIs), which are being used therapeutically to treat patients with CML, has led to the development of second generation TKIs." - Anonymous Online Contributor
"Symptoms of leukemia, myeloid, chronic-phase include fever, chills, night sweats, weight loss, feeling tired, and headache. A complete blood count (CBC), bone marrow biopsy, and chest x-ray should be performed in all cases of unexplained fever, night sweats, and weight loss. A bone marrow examination, peripheral blood smear, and bone marrow aspiration should be performed in cases of unexplained fatigue, headache, and malaise; however, if no abnormality is found on a CBC, a peripheral blood smear, and a bone marrow examination, a chest x-ray should be performed." - Anonymous Online Contributor
"For many people with hematological malignancies, chemotherapy seems to provide remission and prolong survival. In a recent study, we found that there is no difference between local therapy and systemic therapy. Future studies should focus on the role of early intervention before the development of leukemia-associated complications and use of different approaches to enhance the quality of life of long-term survivors." - Anonymous Online Contributor
"A significant proportion of patients die from acute leukemic crisis (ALC). Because ALC is potentially life-threatening, even mild symptoms warrant urgent treatment. As ALC progresses, patients become increasingly frail and may benefit from palliative care." - Anonymous Online Contributor
"A diagnosis of acute myelogenous leukemia has been shown to change prognosis only if the disease has not yet invaded the bone marrow; this is complicated because solid tumors such as cancers of the liver, lung, brain, and breast are capable of infiltrating the bone marrow without interfering with its function. Therefore, in many patients, blood counts continue to rise even after chemotherapy has begun, indicating that leukemia cells are still alive and reproducing despite therapy. It is possible that the initial spread of cancer into the bone marrow occurs rapidly (within days), but the bulk of disease growth takes place more slowly." - Anonymous Online Contributor
"Decitabine is well tolerated and appears to be an active agent for the treatment of MDS. The combination of decitabine and cyclophosphamide showed promising activity in our study. There was no evidence of biosafety issues when using decitabine in combination with cyclophosphamide. Decitabine plus azacitidine should be considered in future clinical trials." - Anonymous Online Contributor
"As mentioned above, clinical trials for leukemia, myeloid, chronic phase may be considered for individuals who have been previously treated, given the high toxicity associated with conventional chemotherapy. In addition, clinical trials could be considered for individuals who do not fit the criteria for aforementioned clinical trials. For example, in the case of acute myeloid leukemia (AML), age < 60 years, performance status 0-2, and one remission prior to enrollment in a clinical trial. Clinical trials for AML may be considered for elderly patients (> 60 years old) experiencing an < 50% remission rate after two cycles of induction chemotherapy." - Anonymous Online Contributor
"The primary cause of [acute lymphoblastic leukemia](https://www.withpower.com/clinical-trials/acute-lymphoblastic-leukemia) was associated with an increased frequency of chromosome translocations and other genetic abnormalities. The majority of relapsed acute myeloid leukemias were preceded by transient myeloproliferative disorders. The primary cause of chronic myelogenous leukemia was the acquisition of a Philadelphia chromosome. The primary cause of chronic lymphocytic leukemia was the B-cell lineage." - Anonymous Online Contributor